Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis

Lopes, Daniela; Falcão, Luiz Menezes

doi:10.1016/j.repc.2016.11.009

Cited by 13 publications

(9 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A higher sST2 concentration (upper reference limit of 35 ng/ml) provides a substantial predictive risk of cardiovascular events, such as progressive LV failure, hospitalization for HF, and death (64). It is worth noting that measuring sST2 combined with BNP or NT-proBNP is better than merely measuring NT-proBNP, because sST2 has a better predictive value than NT-proBNP in myocardial fibrosis and remodeling, which is a known indicator of HF severity (65,66). Wu et al also reported that the low biological variability of sST2 compared to BNP or NT-proBNP enables serial monitoring of sST2, which is preferred over single measurement (65).…”

Section: Prognosismentioning

confidence: 99%

Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis

Zhang

Zhao

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Biomarkers such as B-type natriuretic peptide (BNP), N-terminal pro-BNP (NT-proBNP), cardiac troponin (cTn), and CK-MB contribute significantly to the diagnosis of cardiovascular disease (CVD). Recent studies have demonstrated that suppression of tumorigenicity 2 (ST2) is associated with CVD, but a meta-analysis of ST2 levels in different CVDs has yet to be conducted. Therefore, the present study aimed to investigate soluble ST2 (sST2) levels in patients with ischemic heart disease (IHD), myocardial infarction (MI), and heart failure (HF). A total of 1,425 studies were searched across four databases, of which 16 studies were included in the meta-analysis. The Newcastle–Ottawa Quality Assessment Scale (NOS) values of all 16 studies were ≥7. The meta-analysis results indicated that the sST2 level was not correlated with IHD (standard mean difference [SMD] = 0.58, 95% confidence interval [95% CI] = 0.00 to 1.16, p = 0.05) or MI (weighted mean difference [WMD] = 0.17, 95% CI = −0.22 to 0.55, p = 0.40) but was significantly associated with HF (WMD = 0.21, 95% CI = 0.04 to 0.38, p = 0.02; I2 = 99%, p < 0.00001). sST2 levels did not differ significantly between patients with IHD or MI and healthy individuals; however, we believe that ST2 could be used as an auxiliary diagnostic biomarker of HF.

show abstract

Section: Prognosismentioning

confidence: 99%

Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis

Zhang

Zhao

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…ADM encodes a 185-amino acid preprohormone, pro-ADM, which after posttranslational modification produces a stable form of ADM , easily measurable in blood samples 22 . Available data show that ADM could have a promising and interesting role as a diagnostic and prognostic biomarker in future 22,32,47 .…”

Section: Discussionmentioning

confidence: 99%

“…ADM can reduce total peripheral resistance, leading to decreased blood pressure and increased heart rate 28 . Its role in blood pressure regulation has been examined in numerous studies 20,22,29 , which demonstrated that adrenomedullin could be a promising biomarker for cardiovascular disease in the future 30–32 .…”

Section: Introductionmentioning

confidence: 99%

Associations of the adrenomedullin gene polymorphism with prehypertension and hypertension in Lithuanian children and adolescents: a cross-sectional study

Šimonytė

Kučienė

Dulskienė

et al. 2019

Sci Rep

View full text Add to dashboard Cite

The aim of this study was to evaluate the association of ADM genetic variant and HBP among Lithuanian adolescents aged 12–15 years. This is a cross-sectional study of a randomly selected sample of 675 12–15-years-old schoolchildren who were surveyed during November 2010 to April 2012 in the baseline survey. Single-nucleotide polymorphism (SNP) of ADM gene (rs7129220) was evaluated using real-time PCR. Logistic regression analyses were used to test the associations of ADM (rs7129220) polymorphism with HBP under four inheritance models based on the Akaike Information Criterion (AIC) and to calculate the odds ratios. In the multivariate analysis, boys carrying ADM AG genotype (vs. carriers of ADM GG genotype), ADM AG + AA genotype (vs. carriers of ADM GG genotype) and ADM AG genotype (vs. carriers of ADM GG + AA genotype) had higher odds of having hypertension in codominant, dominant, and overdominant inheritance models. Girls with ADM AG + AA had increased odds of prehypertension compared to girls with the ADM GG genotype carriers in dominant inheritance model. Significant associations were observed in additive models separately for boys (hypertension) and girls (prehypertension). Our results indicate that ADM gene polymorphism was significantly associated with higher odds of HBP in Lithuanian adolescents aged 12–15 years.

show abstract

“…It represents a stable fragment of ADM that can be used as a surrogate marker of ADM activity [128]. The main physiological effects of ADM are diuresis, natriuresis, and vasodilatation, which make ADM a biomarker of particular interest in patients with heart failure, where excess levels of ADM have been described repeatedly [129,130]. Some studies suggested a superior outcome prediction using MR-proADM compared to commonly used biomarkers, such as natriuretic peptides, in patients with both acute and chronic heart failure [131,132].…”

Section: Mr-proadmmentioning

confidence: 99%

Biomarkers Associated with Cardiovascular Disease in COVID-19

Kaufmann

Ahmed

Burger

et al. 2022

Cells

View full text Add to dashboard Cite

Coronavirus disease-19 (COVID-19) emerged late December 2019 in the city of Wuhan, China and has since spread rapidly all over the world causing a global pandemic. While the respiratory system is the primary target of disease manifestation, COVID-19 has been shown to also affect several other organs, making it a rather complex, multi-system disease. As such, cardiovascular involvement has been a topic of discussion since the beginning of the COVID-19 pandemic, primarily due to early reports of excessive myocardial injury in these patients. Treating physicians are faced with multiple challenges in the management and early triage of patients with COVID-19, as disease severity is highly variable ranging from an asymptomatic infection to critical cases rapidly deteriorating to intensive care treatment or even fatality. Laboratory biomarkers provide important prognostic information which can guide decision making in the emergency department, especially in patients with atypical presentations. Several cardiac biomarkers, most notably high-sensitive cardiac troponin (hs-cTn) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), have emerged as valuable predictors of prognosis in patients with COVID-19. The purpose of this review was to offer a concise summary on prognostic cardiac biomarkers in COVID-19 and discuss whether routine measurements of these biomarkers are warranted upon hospital admission.

show abstract

Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis

Cited by 13 publications

References 45 publications

Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis

Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis

Associations of the adrenomedullin gene polymorphism with prehypertension and hypertension in Lithuanian children and adolescents: a cross-sectional study

Biomarkers Associated with Cardiovascular Disease in COVID-19

Contact Info

Product

Resources

About